(8S,9S,10R,13R,14S,17R)-3-isocyanato-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (8S,9S,10R,13R,14S,17R)-3-isocyanato-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene
• 化学式: C₂₈H₄₅NO
• 分子量: 411.7
• InChiKey: QCZBUIBHKVBYRZ-ULEPMCFASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  29.4
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• VACCINE PREPARATION FOR CANCER TREATMENT
  申请人：Mie University

  公开号：EP2752198A1

  公开（公告）日：2014-07-09

  [Problem] To provide a method of clearly deriving killer T cells and helper T cells in a cancer treatment vaccine in which the vaccine antibody is a synthetic long peptide which is derived from a tumor-specific antigen protein and/or pathogen-derived protein and which simultaneously contains a CD8-positive, cytotoxic T-cell recognizing epitope and a CD4-poritive, helper T-cell recognizing epitope peptide. [Solution] BY simultaneously dosing an immunopotentiating agent with a conjugate of a hydrophobized polysaccharide (the antigen delivery system) to the synthetic long peptide, it is possible to achieve clear derivation of antigen-specific killer T-cells and helper T-cells from the cancer treatment vaccine in which the synthetic long peptide is the antigen.

  [问题]提供一种在癌症治疗疫苗中明确衍生杀伤性T细胞和辅助性T细胞的方法，其中疫苗抗体是一种合成长肽，该长肽来源于肿瘤特异性抗原蛋白和/或病原体衍生蛋白，并且同时包含CD8阳性、细胞毒性T细胞识别表位和CD4阳性、辅助性T细胞识别表位肽。 [解]通过将免疫增强剂与疏水多糖（抗原递送系统）与合成长肽的共轭物同时给药，可以从以合成长肽为抗原的癌症治疗疫苗中明确衍生出抗原特异性杀伤 T 细胞和辅助 T 细胞。